A cross-sectional observational study of lipid profile of cirrhosis of liver patients in a teaching hospital in North Odisha, India
DOI:
https://doi.org/10.18203/2349-3933.ijam20201611Keywords:
Cholesterol, Cirrhosis, High-density lipoproteins, Low density lipoproteins, Lipid profile, TriglycerideAbstract
Background: Lipids are essential component of biological membranes: also a part of free molecules and metabolic regulators which control cellular function and homeostasis in the body. Liver plays a central role in lipid metabolism. Cardiovascular disease (CVD) risk stratification includes serum lipid profile. In the general population; global prevalence of cirrhosis from autopsy studies ranges from 4.5% to 9.5%. Deaths from cirrhosis have been estimated to increase and would make it as the 12th leading cause of death in 2020. Although several studies have been conducted on dyslipidemia in cirrhotics in developed countries, there is a paucity of data in this regard in India.
Methods: This observational study was carried out amongst 60 cirrhosis patients that fulfils the inclusion and exclusion criteria and attended the medicine OPD and admitted in medicine ward of Pandit Raghunath Murmu Medical College and Hospital, Baripada, Dist. Mayurbhanj, Odisha, India from June 2018 to Jan 2019.
Results: In our study we had 52 were male and 8 were female. The average age of the patients in the study was 49.62±13.59 yrs. 91.67 % of the patients were alcoholic. Abdominal distension (93.33%) and ascites (81.67%) were most common presenting complaints. Pallor was present in 65.00% cases. Splenomegaly was present in 29 (48.33%) patients of cirrhosis of liver. Renal dysfunction was present in 22 (36.67%) cases. We found decreased HDLC (<40 mg/ Dl) in 34 (56.67%) cases. Hypolipidemia, in particular decreased HDLC level is also an important risk factor for cardiovascular disease and vascular events.
Conclusions: From this study we can conclude that lipid abnormalities are commonly seen in patients with liver cirrhosis and screening for the same is important for intervention with appropriate therapy to prevent cardiovascular events. Further studies on lipid abnormalities in these patients and the need for treatment are recommended.
References
Chiang JY. Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases. Current opinion in investigational drugs (London, England: 2000). 2005 Oct;6(10):994-1001.
Mehboob F, Ranjha FA, Masud S. Changes in Serum Lipid Profile Among Patients Suffering From Chronic Liver Disease. Annals of King Edward Medical University. 2007;13(3):209.
Jiang ZG, Mukamal K, Tapper E, Robson SC, Tsugawa Y. Low LDL-C and high HDL-C levels are associated with elevated serum transaminases amongst adults in the United States: a crosssectional study. PloS One. 2014;9(1):e85366.
Mandal SK, Sil K, Chatterjee S, Ganguly J, Chatterjee K, Sarkar P, et al. A study on lipid profiles in chronic liver diseases. Nat J Med Res. 2013;3:70-2.
Ghadir MR, Riahin AA, Havaspour A, Nooranipour M, Habibinejad AA. The relationship between lipid profile and severity of liver damage in cirrhotic patients Hepat Mon. 2010;10:285-8.
Sen A, Kumar J, Misra RP, Uddin M, Shukla PC. Lipid profile of patients having non-alcoholic fatty liver disease as per ultrasound findings in north Indian population: A retrospective observational study. J Med Allied Sci. 2013;3:59.
Ashraf S, Naeem S. Frequency of Hypersplenism in Chronic Liver Disease Patients Presenting with Pancytopenia. Special Edition Annals. 2010;16(1).
Melato M, Sasso F, Zanconati F. Liver cirrhosis and liver cancer. A study of their relationship in 2563 autopsies. Zentralbl Pathol. 1993;139:25-30.
Graudal N, Leth P, Marbjerg L, Galloe AM. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med. 1991;230:165-71.
Lim YS, Kim WR. Global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008;12:733-46.
Mathers C, Lopez A, Murray C. Burden of disease and mortality by condition: data, methods, and results for 2001. In: Lopez A, Mathers C, Ezzati M, et al, editors. Global burden of disease and risk factors.Washington (DC): Oxford University Press and the World Bank; 2006:45-93.
Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498-504.
Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J Hepatol. 2006 Jan 1;44(1):111-7.
EASL: Clinical Practice Guidelines. Management of cholestatic liver diseases European Association for the Study of the Liver. J Hepatol. 2009;51:237-67.
Suthar HN, Suthar KD, Mewada BN. Clinical profile of cases of alcoholic liver disease. Int J Med Sci Public Health. 2013;2:394-8.
Sarin SK, Dhingra N, Bansal A, Malhotra S, Guptan RC. Dietary and nutritional abnormalities in alcoholic liver disease: a comparison with chronic alcoholics without liver disease. Am J Gastroenterol. 1997;92(5):777-83.
Pathak OK, Paudel R, Panta OB, Giri BR, Adhikari B. Retrospective study of clinical profile and prognostic indicators in patients of alcoholic liver disease admitted to a tertiary care teaching hospital in western Nepal. Saudi J Gastroenterol. 2009; 15(3):172-5.
Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol. 1981;10:417-41.
Hegde S, Vishnar A, Ramteke GB. Study of clinical and laboratory profile in alcoholic liver disease with emphasis on renal function. Int J Res Med Sci. 2015;3:446-50.
Gonzalez-Casas R, Jones EA, MorenoOtero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol. 2009;15(37):4653-8.
Kujovich JL. Hemostatic defects in end stage liver disease. Crit Care Clin. 2005;21(3):563-87.
Jing-ting Jiang, Ning Xu, Xiao-ying Zhang, Changping Wu. Lipids changes in liver cancer. J Zhejiang Univ Sci B. 2007;8(6):398-409.
Libo Luo, Xiangke Pu, Yongzhong Wang, Ning Xu. Impaired plasma lipid profiles in acute hepatitis. Lipids Health Dis. 2010;9:5.
Muhammed HP, Jayaraj K. Correlation of lipid profile in patients with severity of liver disease: a cross sectional study in a tertiary care hospital. Int J Res Med Sci. 2017;5:326-9.
Breier C, Lisch HJ, Braunsteiner H. Lipoproteins, HDLapolopoproteins, activities of hepatic lipase and lecithincholesterol acyltransferase in the plasma of patients with postalcoholic end-stage liver cirrhosis. Klin Wochenschr. 1983 Sep 15;61(18):929-31.
Selimoglu MA, Aydogdu S, Yagci RV. Lipid parameters in childhood cirrhosis and chronic liver disease. Pediatr Int. 2002;44(4):400-3
Valerio Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A, Feldstein AE. Severity of Liver Injury and Atherogenic Lipid Profile in Children With Nonalcoholic Fatty Liver Disease. Pediatric Research .2010; 67: 665–670.
Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med. 1997; 157:792-6.
Rini GB, Averna MR, Montalto G, Di Fede G, Notarbartolo A. Serum lipoprotein fractions in chronic liver diseases with and without alcoholism. Boll Soc Ital Biol Sper. 1981;57:1692-7.
Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart. 2002;87:9-15.
